Myeloperoxidase-mediated dysfunctional high-density lipoprotein

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 4, 2014, Pages 695-696

  Getz, Godfrey S ^a   Reardon, Catherine A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

apoA I; atherosclerosis; cholesterol efflux; Editorials; myeloperoxidase

Indexed keywords

APOLIPOPROTEIN A1; MYELOPEROXIDASE;

EDITORIAL; ENZYME METABOLISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEIN FUNCTION;

APOA-I; ATHEROSCLEROSIS; CHOLESTEROL EFFLUX; EDITORIALS; MYELOPEROXIDASE;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CHOLESTEROL; HUMANS; INFLAMMATION; MACROPHAGES; MALE; PEROXIDASE;

EID: 84897085826     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.303282     Document Type: Editorial

References (14)

1. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell. 2001;104:503-516.
2. Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;50:159-165.
3. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595-1604.
4. Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD. High-density lipopro-tein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012;32:2813-2820.
5. Hewing B, Parathath S, Barrett T, et al. Effects of native and myeloperoxidase-modifed apolipoprotein A-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2014;34:779-789.
6. Shao B, Heinecke JW. Impact of HDL oxidation by the myeloperoxidase system on sterol effux by the ABCA1 pathway. J Proteomics. 2011;74:2289-2299.
7. Feig JE, Shang Y, Rotllan N, Vengrenyuk Y, Wu C, Shamir R, Torra IP, Fernandez-Hernando C, Fisher EA, Garabedian MJ. Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PLoS One. 2011;6:e28534.
8. Rader DJ, Tall AR. The not-so-simple HDL story: is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18:1344-1346.
9. Heinecke JW. The not-so-simple HDL story: a new era for quantifying HDL and cardiovascular risk? Nat Med. 2012;18:1346-1347.
10. Lüscher TF, Landmesser U, von Eckardstein A, Fogelman AM. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res. 2014;114:171-182.
11. Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, Hazen SL. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529-541.
12. DiDonato JA, Huang Y, Aulak KS, Even-Or O, Gerstenecker G, Gogonea V, Wu Y, Fox PL, Tang WH, Plow EF, Smith JD, Fisher EA, Hazen SL. Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma. Circulation. 2013;128: 1644-1655.
13. Huang Y, Wu Z, Riwanto M, et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest. 2013;123: 3815-3828.
14. Huang Y, Didonato JA, Levison BS, et al. An abundant dysfunctional apo-lipoprotein A1 in human atheroma. Nat Med. 2014;20:193-203.